Oxidative Damage in Sporadic Colorectal Cancer: Molecular Mapping of Base Excision Repair Glycosylases MUTYH and hOGG1 in Colorectal Cancer Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 May 2022
Historique:
received: 14 04 2022
revised: 16 05 2022
accepted: 17 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

Oxidative stress, oxidative DNA damage and resulting mutations play a role in colorectal carcinogenesis. Impaired equilibrium between DNA damage formation, antioxidant status, and DNA repair capacity is responsible for the accumulation of genetic mutations and genomic instability. The lesion-specific DNA glycosylases, e.g., hOGG1 and MUTYH, initiate the repair of oxidative DNA damage. Hereditary syndromes (MUTYH-associated polyposis, NTHL1-associated tumor syndrome) with germline mutations causing a loss-of-function in base excision repair glycosylases, serve as straight forward evidence on the role of oxidative DNA damage and its repair. Altered or inhibited function of above glycosylases result in an accumulation of oxidative DNA damage and contribute to the adenoma-adenocarcinoma transition. Oxidative DNA damage, unless repaired, often gives rise G:C > T:A mutations in tumor suppressor genes and proto-oncogenes with subsequent occurrence of chromosomal copy-neutral loss of heterozygosity. For instance, G>T transversions in position c.34 of a KRAS gene serves as a pre-screening tool for MUTYH-associated polyposis diagnosis. Since sporadic colorectal cancer represents more complex and heterogenous disease, the situation is more complicated. In the present study we focused on the roles of base excision repair glycosylases (hOGG1, MUTYH) in colorectal cancer patients by investigating tumor and adjacent mucosa tissues. Although we found downregulation of both glycosylases and significantly lower expression of hOGG1 in tumor tissues, accompanied with G>T mutations in KRAS gene, oxidative DNA damage and its repair cannot solely explain the onset of sporadic colorectal cancer. In this respect, other factors (especially microenvironment) per se or in combination with oxidative DNA damage warrant further attention. Base excision repair characteristics determined in colorectal cancer tissues and their association with disease prognosis have been discussed as well.

Identifiants

pubmed: 35628513
pii: ijms23105704
doi: 10.3390/ijms23105704
pmc: PMC9145200
pii:
doi:

Substances chimiques

DNA Glycosylases EC 3.2.2.-
mutY adenine glycosylase EC 3.2.2.-
oxoguanine glycosylase 1, human EC 3.2.2.-
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Grantova agentura Ceske republiky (GACR)
ID : 20-03997S
Organisme : Agentura pro zdravotnicky vyzkum Ceske Republiky, Ministerstvo zravotnictvi
ID : CR NU21-03-00506
Organisme : Karlova Univerzita
ID : UNCE/MED/006
Organisme : Karlova Univerzita Cooperation
ID : No. 43-Surgical Disciplines

Références

Mol Aspects Med. 2019 Oct;69:2-9
pubmed: 31233770
Mol Carcinog. 2019 Sep;58(9):1531-1550
pubmed: 31168912
Environ Mol Mutagen. 2013 Dec;54(9):691-704
pubmed: 24123395
Int J Mol Sci. 2019 Dec 03;20(23):
pubmed: 31816862
Food Chem Toxicol. 2017 Aug;106(Pt B):583-594
pubmed: 27693244
Antioxid Redox Signal. 2013 Jun 20;18(18):2409-19
pubmed: 23216312
Cancer Genet. 2015 Jul-Aug;208(7-8):390-5
pubmed: 26056087
DNA Repair (Amst). 2018 Dec;72:77-85
pubmed: 30314738
DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
pubmed: 17485253
Expert Opin Investig Drugs. 2022 Apr;31(4):415-423
pubmed: 34429006
Mutagenesis. 2020 Jul 11;35(3):221-231
pubmed: 31605533
Nat Rev Genet. 2014 Sep;15(9):585-98
pubmed: 24981601
Clin Cancer Res. 2012 Nov 1;18(21):5878-87
pubmed: 22966016
Int J Cancer. 2013 Oct 15;133(8):1765-75
pubmed: 23400628
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Mutagenesis. 2019 Dec 19;34(4):341-354
pubmed: 31348825
J Cancer Res Clin Oncol. 2012 Sep;138(9):1443-8
pubmed: 22526153
Cancer Discov. 2022 Jun 2;12(6):1542-1559
pubmed: 35412613
PLoS One. 2013 Dec 05;8(12):e80546
pubmed: 24339875
Mutagenesis. 2012 Mar;27(2):225-32
pubmed: 22294771
Sci Rep. 2014 Apr 15;4:4689
pubmed: 24732879
Mutat Res Genet Toxicol Environ Mutagen. 2019 Jul;843:95-110
pubmed: 31421745
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur J Nutr. 2012 Apr;51(3):261-79
pubmed: 22362552
Arq Bras Cir Dig. 2017 Apr-Jun;30(2):98-102
pubmed: 29257843
DNA Repair (Amst). 2019 Nov;83:102673
pubmed: 31387777
Mol Carcinog. 2015 Sep;54(9):769-78
pubmed: 24585457
Carcinogenesis. 2007 Mar;28(3):657-64
pubmed: 17028303
Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):659-670
pubmed: 29970888
Oncotarget. 2015 Oct 27;6(33):34069-70
pubmed: 26431160
Mutat Res Rev Mutat Res. 2015 Jan-Mar;763:212-45
pubmed: 25795122
J Natl Cancer Inst. 2014 Apr 26;106(5):
pubmed: 24771875
Cell Death Dis. 2016 Jun 09;7(6):e2253
pubmed: 27277675
Chromosoma. 2012 Feb;121(1):1-20
pubmed: 22048164
Pharmacogenomics. 2019 Nov;20(17):1225-1233
pubmed: 31691643
Gut. 2007 Apr;56(4):593
pubmed: 17369389
N Engl J Med. 2009 Dec 17;361(25):2449-60
pubmed: 20018966
Science. 2012 Oct 5;338(6103):120-3
pubmed: 22903521
Gastroenterol Res Pract. 2010;2010:789363
pubmed: 21197450
J Mol Diagn. 2006 May;8(2):178-82
pubmed: 16645203
Int J Mol Sci. 2020 Apr 02;21(7):
pubmed: 32252452
Br J Cancer. 2018 Oct;119(7):785-792
pubmed: 30287914
Int J Mol Sci. 2018 Dec 27;20(1):
pubmed: 30591675

Auteurs

Miriam J Kavec (MJ)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, 140 59 Prague, Czech Republic.

Marketa Urbanova (M)

Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic.

Pavol Makovicky (P)

Department of Biology, Faculty of Education, J Selye University, Bratislavska 3322, 945 01 Komarno, Slovakia.

Alena Opattová (A)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Kristyna Tomasova (K)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Michal Kroupa (M)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Klara Kostovcikova (K)

Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.

Anna Siskova (A)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic.

Nazila Navvabi (N)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Michaela Schneiderova (M)

Department of Surgery, General University Hospital in Prague, First Medical Faculty, Charles University, Katerinska 1660, 128 00 Prague, Czech Republic.

Veronika Vymetalkova (V)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Ludmila Vodickova (L)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Pavel Vodicka (P)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00 Pilsen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH